Sorry, this entry is only available in European Spanish. For the sake of viewer convenience, the content is shown below in the alternative language. You may click the link to switch the active language.
La AEMPS publica el informe de posicionamiento terapéutico de eribulina (Halaven®) en el cáncer de mama.